 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Cepheid (CPHD) develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets.
Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures.
The company primarily offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection.
The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories.
The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, womens health, virology, oncology, and genetics. It also provides SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample; and GeneXpert Infinity System for high volume testing.
The company sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; Life Technologies Corporation to develop reagents for use in the USPS BDS program; AstraZeneca plc, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, and others to develop Xpert Carba-R, a rapid diagnostic test; and Paul G. Allen Family Foundation and the BMGF to develop Xpert Ebola, a rapid test that.
Shares have formed a bullish "flag" ahead of the company's earnings report on Thursday of this week. We expect the firm to post strong results causing shares to move higher.
52-Weeks Trading Range: $36.94 - $63.69
Entry Point: $63.50
Stop Loss: $60.30
Target Price: $69.85
CPHD fell below our stop loss. Closed at $56.00
